Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
AssigneeChristian Noe and Ernst Mutschler
InventorsChristian Noe, Ernst Mutschler, Gunter Lambrecht, Michael Elgert, Ruth Irene Elgert, Sittah Czeche, Magali Waelbroeck
Life of this patent
Estimating the term…
Abstract
Disclosed are enantiomerically pure cyclic aminoalcohol esters of arylcycloalkylhydroxycarboxylic acids with at least 90% enantiomeric excess of the (3R,2′R), (3S,2′R), (3R,2′S), or (3S,2′S) configured enantiomer.
Claims58
A method of treatment of obstructive respiratory diseases by inhalative administration of a pharmaceutically suitable salt of the enantiomerically enriched ester (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium in an effective amount to a patient in need thereof.
A method of treatment of obstructive respiratory diseases by inhalative administration of a pharmaceutically suitable salt of the enantiomerically enriched ester (3R,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium in an effective amount to a patient in need thereof.
A method of treatment of obstructive respiratory diseases by inhalative administration of a pharmaceutically suitable salt of the enantiomerically enriched ester (3S,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium in an effective amount to a patient in need thereof.
A method of treatment of obstructive respiratory diseases by inhalative administration of a pharmaceutically suitable salt of the enantiomerically enriched ester (3S,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium in an effective amount to a patient in need thereof.
A method of treatment of spasms of smooth muscles by administration of a pharmaceutically suitable salt of an enantiomerically enriched ester selected from the group consisting of
- (3R,2′R)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium, ((3S,2′R)-)-3-[cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium, (3R,2′R)-3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium, and (3S,2′R)--3-[cyclohexylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium in an effective amount to a patient in need thereof.
Dependencies are inferred from the claim text.